Agnieszka Adamska, Assoc.Prof.

Medical University of Bialystok

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Agnieszka Adamska, Assoc.Prof. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:28 UTC. Open this list on ClinicalTrials.gov

Ph3
NCT05468554 · Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer
Medical University of Bialystok · recruiting · Thyroid Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:28 UTC. The ranking covers the 200 most relevant of 68 PubMed records, and a shared surname and initials can bring in a namesake. All 68 on PubMed

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Lancet · 2017
371 citations
RCR 13.5
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Ann Rheum Dis · 2017
196 citations
RCR 7.5
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Ann Rheum Dis · 2017
192 citations
RCR 7.2
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Lancet · 2018
168 citations
RCR 6.7
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Clin Pharmacokinet · 2015
115 citations
RCR 3.8
Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis.
Allergy · 2011
107 citations
RCR 3.5
Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients.
J Nucl Med · 2021
106 citations
RCR 6.4
Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial.
Clin Exp Allergy · 2010
105 citations
RCR 3.4
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study.
Lancet Neurol · 2022
99 citations
RCR 9.2
A randomized controlled trial of an implantable 2-channel peroneal nerve stimulator on walking speed and activity in poststroke hemiplegia.
Arch Phys Med Rehabil · 2007
90 citations
RCR 3.8